SEC Form 4 · accession 0001494695-26-000018
Candel Therapeutics, Inc. · CADL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul B Manning
Director
Period of report
Jun 30, 2026
Accepted (ET)
Jul 1, 2026 · 4:21 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001841387
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $10.30 | Jun 30, 2026 | A | 2,199 | A | Jul 1, 2026 | Jun 30, 2036 | Common Stock | 2,199 | 2,199 | D |
Explanation of responses
- F1This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant.